Increased PD-L1 Restricts Liver Injury in Nonalcoholic Fatty Liver Disease

Figure 4

Identification of ZNF24–UBE2I protein interactions. (a and b) Analysis of protein interactions between ZNF24 and UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment measured by western blot. (g and h) After FFA treatment, Sumo-1: ZNF24 and ZNF24 expression levels detected by western blot. (i and j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, and UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)